Peptide Romania
longevity

MOTS-c

Mitochondrial-derived peptide linked to metabolic resilience and aging research.

Dovezi
Emerging
T½
~hours
Categorie
longevity
Status
Investigational

Evaluarea dovezilor

Baza de dovezi

Emerging33%

Strong: Multiple studii umane controlate cu rezultate consistente și replicate de grupuri independente de cercetare.

Moderate: Studii umane sau animale cu semnale pozitive; există variabilitate metodologică sau date conflictuale limitate.

Emerging: Cercetare timpurie, predominant preclinică, cu rezultate promițătoare. Confirmarea umană este limitată.

Preliminary: Date foarte limitate, în principal rapoarte exploratorii sau studii singulare fără replicare independentă.

Farmacologie

Mecanism de acțiune

Mitochondrial-derived peptide linked to metabolic resilience and aging research.

T½~hours
StatusInvestigational
Categorielongevity
DoveziEmerging

Întrebări frecvente

Ce trebuie să știi

Mitochondrial-derived peptide linked to metabolic resilience and aging research.
MOTS-c has Emerging evidence. Early-stage research, mostly preclinical, shows promising preliminary results. Human confirmation is limited — findings should be interpreted cautiously by researchers.
The half-life of MOTS-c is ~hours. This determines dosing frequency in research protocols — shorter half-lives require more frequent administration to maintain stable concentrations in study subjects.
MOTS-c is currently classified as: Investigational. Regulatory status varies by jurisdiction — always consult local regulations and a qualified medical professional before any use outside an approved clinical context.
Mitochondrial-derived peptide linked to metabolic resilience and aging research.
Înapoi la peptide